Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» atopic dermatitis
atopic dermatitis
Pfizer's Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent in eczema
Fierce Pharma
Sun, 01/16/22 - 03:53 am
Pfizer
Sanofi
Regeneron
FDA
Cibinqo
atopic dermatitis
Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals
NASDAQ
Tue, 12/21/21 - 10:30 am
Eli Lilly
lebrikizumab
monoclonal antibodies
atopic dermatitis
clinical trials
A Pfizer Drug Moves Closer to Approval in Another Important Indication
Motley Fool
Wed, 11/3/21 - 10:38 am
Cibingo
Pfizer
Europe
eczema
atopic dermatitis
AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis
Endpoints
Tue, 11/2/21 - 10:48 am
atopic dermatitis
eczema
nocturnal scratch
digital endpoint
AbbVie
Janssen
JNJ
Novartis
Pfizer
UCB Pharma
digital pharma
Incyte on a Roll with Two FDA Wins in Two Days
BioSpace
Thu, 09/23/21 - 10:55 pm
Incyte
FDA
Jakafi
graft vs host disease
ruxolitinib
atopic dermatitis
Incyte nabs approval of topical ruxolitinib in atopic dermatitis, but gets slapped with JAK warning
Endpoints
Wed, 09/22/21 - 11:17 am
FDA
Incyte
atopic dermatitis
ruxolitinib
Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo
Pharmaforum
Thu, 09/9/21 - 11:13 pm
Pfizer
Cibinqo
atopic dermatitis
eczema
UK
Xeljanz
Pfizer's abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, but key questions remain
Fierce Biotech
Mon, 08/30/21 - 11:03 am
Pfizer
abrocitinib
atopic dermatitis
Dupixent
Sanofi
Regeneron
clinical trials
AbbVie’s Rinvoq is first JAK drug cleared in EU for atopic dermatitis
Pharmaforum
Wed, 08/25/21 - 09:19 pm
AbbVie
Rinvoq
Europe
atopic dermatitis
FDA
Lilly, swinging at the king, shows Dupixent rival works in phase 3, but wait for key figures goes on
Fierce Biotech
Mon, 08/16/21 - 12:25 pm
Eli Lilly
lebrikizumab
Sanofi
Regeneron
Dupixent
atopic dermatitis
clinical trials
Lilly’s lebrikizumab looks to outdo Dupixent
EP Vantage
Mon, 08/2/21 - 10:48 am
Eli Lilly
lebrikizumab
atopic dermatitis
Dupixent
Sanofi
Regeneron
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
Yahoo/Benzinga
Sun, 07/18/21 - 09:45 pm
AbbVie
Eli Lilly
atopic dermatitis
FDA
Rinvoq
olumiant
Incyte hits 2nd FDA delay in span of days, this time for atopic dermatitis hopeful ruxolitinib cream
Fierce Pharma
Sat, 06/12/21 - 10:23 pm
Incyte
atopic dermatitis
ruxolitinib
FDA
Amgen follows Sanofi into a new dermatitis mechanism
EP Vantage
Tue, 06/1/21 - 10:58 am
Amgen
Sanofi
atopic dermatitis
Ichnos
KHK4083
Kyowa Kirin
AbbVie, building out its post-Humira future, posts 5 late-stage trial wins for Skyrizi and Rinvoq
Fierce Pharma
Wed, 05/26/21 - 12:05 pm
AbbVie
Humira
drug pricing
patents
immunology
Skyrizi
Rinvoq
clinical trials
Crohn's Disease
atopic dermatitis
Leo Pharma’s Tralokinumab News: What You Need to Know
BioSpace
Thu, 05/20/21 - 11:10 pm
LEO Pharma
Adtralza
FDA
atopic dermatitis
Cara's stock tanks as atopic dermatitis phase 2 misses endpoint
Fierce Biotech
Fri, 04/30/21 - 10:45 am
Cara Therapeutics
atopic dermatitis
eczema
clinical trials
Korsuva
FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate
Endpoints
Fri, 04/30/21 - 10:43 am
LEO Pharma
FDA
atopic dermatitis
eczema
monoclonal antibodies
Dupixent
Sanofi inks $1.1B Kymab buyout to bag midphase eczema drug
Fierce Biotech
Mon, 01/11/21 - 09:57 am
Sanofi
Kymab
M&A
atopic dermatitis
eczema
monoclonal antibodies
Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib
Endpoints
Wed, 11/11/20 - 11:04 am
Pfizer
JAK inhibitors
abrocitinib
Dupixent
atopic dermatitis
clinical trials
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »